Diversified Trust Co increased its stake in shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 20.4% during the second quarter, Holdings Channel reports. The fund owned 57,607 shares of the company’s stock after buying an additional 9,770 shares during the period. Diversified Trust Co’s holdings in Teva Pharmaceutical Industries were worth $2,894,000 as of its most recent SEC filing.

Several other institutional investors also recently made changes to their positions in TEVA. Narwhal Capital Management boosted its stake in shares of Teva Pharmaceutical Industries by 32.2% in the second quarter. Narwhal Capital Management now owns 72,510 shares of the company’s stock worth $3,642,000 after buying an additional 17,660 shares during the last quarter. PGGM Investments boosted its stake in shares of Teva Pharmaceutical Industries by 64.7% in the second quarter. PGGM Investments now owns 1,344,928 shares of the company’s stock worth $67,556,000 after buying an additional 528,470 shares during the last quarter. Strs Ohio boosted its stake in shares of Teva Pharmaceutical Industries by 3.5% in the second quarter. Strs Ohio now owns 630,593 shares of the company’s stock worth $31,674,000 after buying an additional 21,091 shares during the last quarter. Seven Bridges Advisors LLC boosted its stake in shares of Teva Pharmaceutical Industries by 33.8% in the second quarter. Seven Bridges Advisors LLC now owns 22,503 shares of the company’s stock worth $1,130,000 after buying an additional 5,681 shares during the last quarter. Finally, Butensky & Cohen Financial Security Inc. boosted its stake in shares of Teva Pharmaceutical Industries by 6.2% in the second quarter. Butensky & Cohen Financial Security Inc. now owns 25,842 shares of the company’s stock worth $1,298,000 after buying an additional 1,515 shares during the last quarter.

Shares of Teva Pharmaceutical Industries Ltd (NYSE:TEVA) traded up 1.49% during trading on Thursday, hitting $51.23. The stock had a trading volume of 2,969,972 shares. The stock’s 50-day moving average price is $52.11 and its 200-day moving average price is $53.25. Teva Pharmaceutical Industries Ltd has a one year low of $48.01 and a one year high of $66.55. The company has a market cap of $46.82 billion, a P/E ratio of 34.22 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Thursday, August 4th. The company reported $1.25 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.20 by $0.05. The business had revenue of $5 billion for the quarter, compared to analysts’ expectations of $4.86 billion. During the same quarter last year, the company posted $1.43 earnings per share. The business’s quarterly revenue was up 1.4% compared to the same quarter last year. On average, equities research analysts forecast that Teva Pharmaceutical Industries Ltd will post $5.26 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 8th. Investors of record on Monday, August 22nd were given a dividend of $0.34 per share. The ex-dividend date was Thursday, August 18th. This represents a $1.36 annualized dividend and a yield of 2.65%.

A number of research firms recently issued reports on TEVA. Mizuho reissued a “buy” rating on shares of Teva Pharmaceutical Industries in a research note on Sunday, July 17th. Piper Jaffray Cos. reissued a “hold” rating and issued a $58.00 price target on shares of Teva Pharmaceutical Industries in a research note on Tuesday, May 31st. Credit Suisse Group AG reissued a “hold” rating on shares of Teva Pharmaceutical Industries in a research note on Tuesday, May 31st. RBC Capital Markets set a $71.00 price target on shares of Teva Pharmaceutical Industries and gave the company a “buy” rating in a research note on Sunday, September 11th. Finally, Wells Fargo & Co. reissued a “buy” rating on shares of Teva Pharmaceutical Industries in a research note on Tuesday, May 31st. Seven research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $67.54.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a global pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. It has a global portfolio of approximately 1,000 molecules.

5 Day Chart for NYSE:TEVA

Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).

Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related companies with MarketBeat.com's FREE daily email newsletter.